441 related articles for article (PubMed ID: 32717289)
1. Obeticholic acid improves hepatic bile acid excretion in patients with primary biliary cholangitis.
Kjærgaard K; Frisch K; Sørensen M; Munk OL; Hofmann AF; Horsager J; Schacht AC; Erickson M; Shapiro D; Keiding S
J Hepatol; 2021 Jan; 74(1):58-65. PubMed ID: 32717289
[TBL] [Abstract][Full Text] [Related]
2. Obeticholic acid-a new therapy in PBC and NASH.
Chapman RW; Lynch KD
Br Med Bull; 2020 May; 133(1):95-104. PubMed ID: 32282030
[TBL] [Abstract][Full Text] [Related]
3. A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis.
Kowdley KV; Vuppalanchi R; Levy C; Floreani A; Andreone P; LaRusso NF; Shrestha R; Trotter J; Goldberg D; Rushbrook S; Hirschfield GM; Schiano T; Jin Y; Pencek R; MacConell L; Shapiro D; Bowlus CL;
J Hepatol; 2020 Jul; 73(1):94-101. PubMed ID: 32165251
[TBL] [Abstract][Full Text] [Related]
4. Obeticholic acid for the treatment of primary biliary cholangitis.
Ali AH; Lindor KD
Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
[TBL] [Abstract][Full Text] [Related]
5. Hepatobiliary transport kinetics of the conjugated bile acid tracer
Ørntoft NW; Munk OL; Frisch K; Ott P; Keiding S; Sørensen M
J Hepatol; 2017 Aug; 67(2):321-327. PubMed ID: 28249726
[TBL] [Abstract][Full Text] [Related]
6. Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models.
Zhang Y; LaCerte C; Kansra S; Jackson JP; Brouwer KR; Edwards JE
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226620
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid.
Hirschfield GM; Mason A; Luketic V; Lindor K; Gordon SC; Mayo M; Kowdley KV; Vincent C; Bodhenheimer HC; Parés A; Trauner M; Marschall HU; Adorini L; Sciacca C; Beecher-Jones T; Castelloe E; Böhm O; Shapiro D
Gastroenterology; 2015 Apr; 148(4):751-61.e8. PubMed ID: 25500425
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis.
Kowdley KV; Luketic V; Chapman R; Hirschfield GM; Poupon R; Schramm C; Vincent C; Rust C; Parés A; Mason A; Marschall HU; Shapiro D; Adorini L; Sciacca C; Beecher-Jones T; Böhm O; Pencek R; Jones D;
Hepatology; 2018 May; 67(5):1890-1902. PubMed ID: 29023915
[TBL] [Abstract][Full Text] [Related]
9. Obeticholic acid in primary biliary cholangitis: where we stand.
Manne V; Kowdley KV
Curr Opin Gastroenterol; 2019 May; 35(3):191-196. PubMed ID: 30844895
[TBL] [Abstract][Full Text] [Related]
10. Hepatic bile acid transport increases in the postprandial state: A functional
Ørntoft NW; Gormsen LC; Keiding S; Munk OL; Ott P; Sørensen M
JHEP Rep; 2021 Jun; 3(3):100288. PubMed ID: 34095797
[TBL] [Abstract][Full Text] [Related]
11. Novel Aspects in the Management of Cholestatic Liver Diseases.
Chazouillères O
Dig Dis; 2016; 34(4):340-6. PubMed ID: 27170387
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease.
Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D
Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264
[TBL] [Abstract][Full Text] [Related]
13. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.
Nevens F; Andreone P; Mazzella G; Strasser SI; Bowlus C; Invernizzi P; Drenth JP; Pockros PJ; Regula J; Beuers U; Trauner M; Jones DE; Floreani A; Hohenester S; Luketic V; Shiffman M; van Erpecum KJ; Vargas V; Vincent C; Hirschfield GM; Shah H; Hansen B; Lindor KD; Marschall HU; Kowdley KV; Hooshmand-Rad R; Marmon T; Sheeron S; Pencek R; MacConell L; Pruzanski M; Shapiro D;
N Engl J Med; 2016 Aug; 375(7):631-43. PubMed ID: 27532829
[TBL] [Abstract][Full Text] [Related]
14. Obeticholic acid for the treatment of primary biliary cirrhosis.
Trivedi PJ; Hirschfield GM; Gershwin ME
Expert Rev Clin Pharmacol; 2016; 9(1):13-26. PubMed ID: 26549695
[TBL] [Abstract][Full Text] [Related]
15. Obeticholic acid may increase the risk of gallstone formation in susceptible patients.
Al-Dury S; Wahlström A; Panzitt K; Thorell A; Ståhlman M; Trauner M; Fickert P; Bäckhed F; Fändriks L; Wagner M; Marschall HU
J Hepatol; 2019 Nov; 71(5):986-991. PubMed ID: 31254596
[TBL] [Abstract][Full Text] [Related]
16. Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms.
Guo C; LaCerte C; Edwards JE; Brouwer KR; Brouwer KLR
J Pharmacol Exp Ther; 2018 May; 365(2):413-421. PubMed ID: 29487110
[TBL] [Abstract][Full Text] [Related]
17. Primary Biliary Cholangitis: Medical and Specialty Pharmacy Management Update.
Bowlus CL; Kenney JT; Rice G; Navarro R
J Manag Care Spec Pharm; 2016 Oct; 22(10-a-s Suppl):S3-S15. PubMed ID: 27700211
[TBL] [Abstract][Full Text] [Related]
18. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
19. Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis.
Silveira MG; Lindor KD
Expert Opin Pharmacother; 2014 Feb; 15(3):365-72. PubMed ID: 24382005
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis.
Bowlus CL; Pockros PJ; Kremer AE; Parés A; Forman LM; Drenth JPH; Ryder SD; Terracciano L; Jin Y; Liberman A; Pencek R; Iloeje U; MacConell L; Bedossa P
Clin Gastroenterol Hepatol; 2020 May; 18(5):1170-1178.e6. PubMed ID: 31606455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
